1. Home
  2. MGYR vs AGEN Comparison

MGYR vs AGEN Comparison

Compare MGYR & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Magyar Bancorp Inc.

MGYR

Magyar Bancorp Inc.

N/A

Current Price

$17.55

Market Cap

112.7M

Sector

Finance

ML Signal

N/A

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$3.39

Market Cap

147.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGYR
AGEN
Founded
1922
1994
Country
United States
United States
Employees
98
N/A
Industry
Savings Institutions
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
112.7M
147.4M
IPO Year
2021
1999

Fundamental Metrics

Financial Performance
Metric
MGYR
AGEN
Price
$17.55
$3.39
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$14.50
AVG Volume (30 Days)
2.2K
1.1M
Earning Date
04-23-2026
05-12-2026
Dividend Yield
2.30%
N/A
EPS Growth
26.83
100.00
EPS
0.50
1.02
Revenue
N/A
$42,877,086.00
Revenue This Year
N/A
$107.63
Revenue Next Year
N/A
N/A
P/E Ratio
$34.80
$8.89
Revenue Growth
N/A
89.95
52 Week Low
$15.22
$2.71
52 Week High
$20.00
$7.34

Technical Indicators

Market Signals
Indicator
MGYR
AGEN
Relative Strength Index (RSI) 50.16 42.06
Support Level $17.04 $2.91
Resistance Level $17.99 $4.72
Average True Range (ATR) 0.15 0.29
MACD -0.01 -0.09
Stochastic Oscillator 47.79 17.88

Price Performance

Historical Comparison
MGYR
AGEN

About MGYR Magyar Bancorp Inc.

Magyar Bancorp Inc is an independent, community financial services provider offering traditional banking services to individual, business, and government customers. The Company attracts retail deposits through its main office in New Brunswick, New Jersey, and branch offices in Middlesex and Somerset Counties, and invests those funds mainly in commercial and residential real estate loans, commercial business loans, SBA loans, home equity loans and lines of credit, construction and land loans, and investment securities. Revenues are derived mainly from interest on loans and securities and from fees and service charges, with lending relationships focused on small to mid-sized businesses and individual consumers in central and northern New Jersey.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: